- Teens who wish to take tenofovir/emtricitabine (Truvada) for HIV prevention should be followed carefully for bone mineral density (BMD) effects.
Why this matters
- Tenofovir (Viread) is known to worsen renal function and decrease bone density in adults, but little information is available on teens.
- BMD declined significantly at 24 and 48 wk.
- 2 participants sustained fractures during study period after trauma.
- BMD declines were more pronounced among people with high levels of drug exposure, especially in total hip BMD.
- BMD changes were correlated with drug concentrations at 12 wk, 24 wk, and 48 wk.
- Estimated glomerular filtration rate and other markers of renal function did not change significantly during study.
- Despite lack of changes to serum creatinine or eGFR, endocrine markers changed significantly by 8 wk in the high-adherence group.
- Subanalysis of randomized controlled trial.
- 101 young men who have sex with men without HIV enrolled in the ATN 117 study.
- Funding: NIH.
- Sample size is modest, limiting the power of these findings.
- Number of participants with significant drug concentrations was small.